Drug Profile
AZD 2327
Alternative Names: AZD2327Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antidepressants; Anxiolytics
- Mechanism of Action Opioid delta receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders; Depressive disorders
Most Recent Events
- 27 Jan 2011 Discontinued - Phase-II for Anxiety disorders in USA (PO)
- 27 Jan 2011 Discontinued - Phase-II for Depressive disorders in USA (PO)
- 31 Jan 2009 Phase-II clinical trials in Anxiety disorders in USA (PO)